Logo image of AVIR

ATEA PHARMACEUTICALS INC (AVIR) Stock Fundamental Analysis

NASDAQ:AVIR - US04683R1068 - Common Stock

3.575 USD
-0.07 (-2.05%)
Last: 8/27/2025, 2:30:32 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AVIR. AVIR was compared to 193 industry peers in the Pharmaceuticals industry. AVIR has a great financial health rating, but its profitability evaluates not so good. AVIR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AVIR has reported negative net income.
AVIR had a negative operating cash flow in the past year.
AVIR had negative earnings in 4 of the past 5 years.
AVIR had negative operating cash flow in 4 of the past 5 years.
AVIR Yearly Net Income VS EBIT VS OCF VS FCFAVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.76%, AVIR is in line with its industry, outperforming 47.67% of the companies in the same industry.
With a Return On Equity value of -37.35%, AVIR perfoms like the industry average, outperforming 57.51% of the companies in the same industry.
Industry RankSector Rank
ROA -34.76%
ROE -37.35%
ROIC N/A
ROA(3y)-25.47%
ROA(5y)-12.4%
ROE(3y)-26.96%
ROE(5y)-13.16%
ROIC(3y)N/A
ROIC(5y)N/A
AVIR Yearly ROA, ROE, ROICAVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

AVIR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVIR Yearly Profit, Operating, Gross MarginsAVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

AVIR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AVIR has more shares outstanding
There is no outstanding debt for AVIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVIR Yearly Shares OutstandingAVIR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVIR Yearly Total Debt VS Total AssetsAVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

AVIR has an Altman-Z score of 4.73. This indicates that AVIR is financially healthy and has little risk of bankruptcy at the moment.
AVIR's Altman-Z score of 4.73 is fine compared to the rest of the industry. AVIR outperforms 78.24% of its industry peers.
AVIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.73
ROIC/WACCN/A
WACCN/A
AVIR Yearly LT Debt VS Equity VS FCFAVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

AVIR has a Current Ratio of 19.17. This indicates that AVIR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AVIR (19.17) is better than 89.12% of its industry peers.
A Quick Ratio of 19.17 indicates that AVIR has no problem at all paying its short term obligations.
AVIR's Quick ratio of 19.17 is amongst the best of the industry. AVIR outperforms 89.12% of its industry peers.
Industry RankSector Rank
Current Ratio 19.17
Quick Ratio 19.17
AVIR Yearly Current Assets VS Current LiabilitesAVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.33% over the past year.
EPS 1Y (TTM)23.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AVIR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.41% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.28%
EPS Next 2Y6.2%
EPS Next 3Y4.41%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVIR Yearly Revenue VS EstimatesAVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2027 100M 200M 300M
AVIR Yearly EPS VS EstimatesAVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AVIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AVIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVIR Price Earnings VS Forward Price EarningsAVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVIR Per share dataAVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.2%
EPS Next 3Y4.41%

More info and screens

0

5. Dividend

5.1 Amount

AVIR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATEA PHARMACEUTICALS INC

NASDAQ:AVIR (8/27/2025, 2:30:32 PM)

3.575

-0.07 (-2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners62.97%
Inst Owner Change-0.56%
Ins Owners4.94%
Ins Owner Change5.22%
Market Cap283.71M
Analysts82.5
Price Target6.12 (71.19%)
Short Float %5.91%
Short Ratio11.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.25%
Min EPS beat(2)4.14%
Max EPS beat(2)4.35%
EPS beat(4)3
Avg EPS beat(4)7.31%
Min EPS beat(4)-5.99%
Max EPS beat(4)26.72%
EPS beat(8)6
Avg EPS beat(8)8.93%
EPS beat(12)10
Avg EPS beat(12)16.73%
EPS beat(16)13
Avg EPS beat(16)24.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)70.67%
EPS NQ rev (3m)-12.82%
EPS NY rev (1m)39.01%
EPS NY rev (3m)24.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-1.61
EYN/A
EPS(NY)-1.74
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0
BVpS4.59
TBVpS4.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.76%
ROE -37.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.47%
ROA(5y)-12.4%
ROE(3y)-26.96%
ROE(5y)-13.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.17
Quick Ratio 19.17
Altman-Z 4.73
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
EPS Next Y12.28%
EPS Next 2Y6.2%
EPS Next 3Y4.41%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.28%
EBIT Next 3Y15.29%
EBIT Next 5YN/A
FCF growth 1Y-31.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.68%
OCF growth 3YN/A
OCF growth 5YN/A